Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel

Jilaveanu, LB and Zhao, F and Zito, CR and Kirkwood, JM and Nathanson, KL and D'Andrea, K and Wilson, M and Rimm, DL and Flaherty, KT and Lee, SJ and Kluger, HM (2013) Expression of Drug Targets in Patients Treated with Sorafenib, Carboplatin and Paclitaxel. PLoS ONE, 8 (8).

Available under License : See the attached license file.

Download (227kB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)


Introduction: Sorafenib, a multitarget kinase inhibitor, targets members of the mitogen-activated protein kinase (MAPK) pathway and VEGFR kinases. Here we assessed the association between expression of sorafenib targets and biomarkers of taxane sensitivity and response to therapy in pre-treatment tumors from patients enrolled in ECOG 2603, a phase III comparing sorafenib, carboplatin and paclitaxel (SCP) to carboplatin, paclitaxel and placebo (CP). Methods: Using a method of automated quantitative analysis (AQUA) of in situ protein expression, we quantified expression of VEGF-R2, VEGF-R1, VEGF-R3, FGF-R1, PDGF-Rβ, c-Kit, B-Raf, C-Raf, MEK1, ERK1/2, STMN1, MAP2, EB1 and Bcl-2 in pretreatment specimens from 263 patients. Results: An association was found between high FGF-R1 and VEGF-R1 and increased progression-free survival (PFS) and overall survival (OS) in our combined cohort (SCP and CP arms). Expression of FGF-R1 and VEGF-R1 was higher in patients who responded to therapy ((CR+PR) vs. (SD+PD+ un-evaluable)). Conclusions: In light of the absence of treatment effect associated with sorafenib, the association found between FGF-R1 and VEGF-R1 expression and OS, PFS and response might reflect a predictive biomarker signature for carboplatin/paclitaxel-based therapy. Seeing that carboplatin and pacitaxel are now widely used for this disease, corroboration in another cohort might enable us to improve the therapeutic ratio of this regimen. © 2013 Jilaveanu et al.


Social Networking:
Share |


Item Type: Article
Status: Published
CreatorsEmailPitt UsernameORCID
Jilaveanu, LB
Zhao, F
Zito, CR
Kirkwood, JMkirkwood@pitt.eduKIRKWOOD
Nathanson, KL
D'Andrea, K
Wilson, M
Rimm, DL
Flaherty, KT
Lee, SJ
Kluger, HM
Centers: Other Centers, Institutes, Offices, or Units > Hillman Cancer Center
Date: 6 August 2013
Date Type: Publication
Journal or Publication Title: PLoS ONE
Volume: 8
Number: 8
DOI or Unique Handle: 10.1371/journal.pone.0069748
Refereed: Yes
Date Deposited: 23 Sep 2013 17:52
Last Modified: 19 Feb 2019 05:55


Monthly Views for the past 3 years

Plum Analytics

Actions (login required)

View Item View Item